** U.S.-listed shares of Switzerland-based drug developer Oculis Holding CR5.F, OCS.O rise 6.8% to $18.75 premarket
** Co says its drug, OCS-05, met the main goal of safety in a mid-stage trial testing it in patients with acute optic neuritis, an inflammatory condition that causes sudden vision loss
** Says the drug also improved patients' visual function during the trial
** Up to last close, stock up 66.3% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.